JP2021504466A - 頻脈の治療 - Google Patents

頻脈の治療 Download PDF

Info

Publication number
JP2021504466A
JP2021504466A JP2020545878A JP2020545878A JP2021504466A JP 2021504466 A JP2021504466 A JP 2021504466A JP 2020545878 A JP2020545878 A JP 2020545878A JP 2020545878 A JP2020545878 A JP 2020545878A JP 2021504466 A JP2021504466 A JP 2021504466A
Authority
JP
Japan
Prior art keywords
pde2
treatment
tachycardia
subject
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020545878A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021504466A5 (https=
Inventor
ヤン マグヌス アロンセン
ヤン マグヌス アロンセン
ヨナス スコグスタッド
ヨナス スコグスタッド
Original Assignee
オスロ ウニヴェルシティ ホスピタル ホーエフ
オスロ ウニヴェルシティ ホスピタル ホーエフ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オスロ ウニヴェルシティ ホスピタル ホーエフ, オスロ ウニヴェルシティ ホスピタル ホーエフ filed Critical オスロ ウニヴェルシティ ホスピタル ホーエフ
Publication of JP2021504466A publication Critical patent/JP2021504466A/ja
Publication of JP2021504466A5 publication Critical patent/JP2021504466A5/ja
Priority to JP2023188086A priority Critical patent/JP2024012483A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020545878A 2017-11-23 2018-11-23 頻脈の治療 Pending JP2021504466A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023188086A JP2024012483A (ja) 2017-11-23 2023-11-02 頻脈の治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17203377.1 2017-11-23
EP17203377 2017-11-23
PCT/EP2018/082450 WO2019101970A1 (en) 2017-11-23 2018-11-23 Treatment of tachycardia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023188086A Division JP2024012483A (ja) 2017-11-23 2023-11-02 頻脈の治療

Publications (2)

Publication Number Publication Date
JP2021504466A true JP2021504466A (ja) 2021-02-15
JP2021504466A5 JP2021504466A5 (https=) 2022-01-06

Family

ID=60452486

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020545878A Pending JP2021504466A (ja) 2017-11-23 2018-11-23 頻脈の治療
JP2023188086A Pending JP2024012483A (ja) 2017-11-23 2023-11-02 頻脈の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023188086A Pending JP2024012483A (ja) 2017-11-23 2023-11-02 頻脈の治療

Country Status (12)

Country Link
US (2) US11419874B2 (https=)
EP (1) EP3713572B1 (https=)
JP (2) JP2021504466A (https=)
CN (1) CN111447930A (https=)
AU (1) AU2018371216B2 (https=)
CA (1) CA3083176A1 (https=)
DK (1) DK3713572T3 (https=)
ES (1) ES3039584T3 (https=)
FI (1) FI3713572T3 (https=)
PL (1) PL3713572T3 (https=)
PT (1) PT3713572T (https=)
WO (1) WO2019101970A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11219642B1 (en) * 2020-09-01 2022-01-11 Catherine Lueninghoener Methods and compositions for treating heart conditions
CN113063804B (zh) * 2021-03-16 2022-07-15 太原科技大学 一种基于图像处理的热切机视觉系统自动定位方法
EP4334293A1 (en) * 2021-05-07 2024-03-13 Merck Sharp & Dohme LLC Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006519243A (ja) * 2003-03-04 2006-08-24 アルタナ　ファルマ　アクチエンゲゼルシャフト プリン−６−オン誘導体
JP2008511586A (ja) * 2004-09-02 2008-04-17 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング トリアゾロフタラジン
JP2017114764A (ja) * 2014-04-25 2017-06-29 武田薬品工業株式会社 片頭痛治療剤

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10064105A1 (de) 2000-12-21 2002-06-27 Bayer Ag Neue Substituierte Imidazotriazinone
US20060128695A1 (en) 2002-10-30 2006-06-15 Neuro3D Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses
AU2004268387A1 (en) 2003-08-28 2005-03-10 Nycomed Gmbh Composition comprising a pulmonary surfactant and a PDE2 inhibitor
WO2005035505A2 (en) 2003-09-30 2005-04-21 Artesian Therapeutics, Inc. Compounds with phosphodiesterase inhibiting and calcium channel blocking activities
WO2005041957A1 (en) 2003-10-29 2005-05-12 Pfizer Products Inc. Oxindole derivatives and their use as phosphodiesterase type 2 inhibitors
ATE387446T1 (de) 2003-12-16 2008-03-15 Pfizer Prod Inc Pyrido(2,3-d)pyrimidin-2,4-diamine als pde-2- inhibitoren
EP1548011A1 (en) 2003-12-23 2005-06-29 Neuro3D Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof
EP1874775B1 (en) 2005-01-05 2012-10-10 Nycomed GmbH Triazolophthalazines as pde2-inhibitors
BRPI0606379A2 (pt) 2005-01-05 2009-06-23 Nycomed Gmbh triazolftalazinas
EP1749824A1 (en) 2005-08-03 2007-02-07 Neuro3D Benzodiazepine derivatives, their preparation and the therapeutic use thereof
DE102006048693A1 (de) 2006-10-14 2008-04-17 Bayer Healthcare Ag Inhibition der PDE2A
EP2279009A4 (en) * 2008-05-05 2011-09-21 Univ Rochester METHOD AND COMPOSITIONS FOR TREATING OR PREVENTING PATHOLOGICAL CARDIAL REMODELING AND HEART FAILURE
US20100120762A1 (en) 2008-11-07 2010-05-13 Wyeth Triazine derivatives as inhibitors of phosphodiesterases
US9540379B2 (en) 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
KR101548443B1 (ko) 2011-02-23 2015-08-28 화이자 인코포레이티드 신경 장애의 치료를 위한 이미다조[5,1-f][1,2,4]트라이아진
SG195085A1 (en) 2011-06-07 2013-12-30 Pfizer Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors
BR112013033375B1 (pt) 2011-06-27 2022-05-10 Janssen Pharmaceutica N.V Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário
MX361539B (es) 2012-04-25 2018-12-10 Takeda Pharmaceuticals Co Compuesto heterociclico nitrogenado.
EP2873669A4 (en) 2012-07-13 2015-11-25 Takeda Pharmaceutical HETEROCYCLIC CONNECTION
US20140045856A1 (en) 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
JPWO2015012328A1 (ja) 2013-07-24 2017-03-02 武田薬品工業株式会社 複素環化合物
US10239882B2 (en) 2014-11-05 2019-03-26 Dart Neuroscience (Cayman) Ltd. Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006519243A (ja) * 2003-03-04 2006-08-24 アルタナ　ファルマ　アクチエンゲゼルシャフト プリン−６−オン誘導体
JP2008511586A (ja) * 2004-09-02 2008-04-17 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング トリアゾロフタラジン
JP2017114764A (ja) * 2014-04-25 2017-06-29 武田薬品工業株式会社 片頭痛治療剤

Also Published As

Publication number Publication date
CN111447930A (zh) 2020-07-24
ES3039584T3 (en) 2025-10-22
DK3713572T3 (da) 2025-08-25
US20200345744A1 (en) 2020-11-05
PT3713572T (pt) 2025-08-28
EP3713572A1 (en) 2020-09-30
JP2024012483A (ja) 2024-01-30
PL3713572T3 (pl) 2025-09-22
US11419874B2 (en) 2022-08-23
AU2018371216A1 (en) 2020-06-04
EP3713572B1 (en) 2025-07-30
WO2019101970A1 (en) 2019-05-31
CA3083176A1 (en) 2019-05-31
US20220362251A1 (en) 2022-11-17
FI3713572T3 (fi) 2025-09-09
AU2018371216B2 (en) 2024-09-19

Similar Documents

Publication Publication Date Title
JP2024012483A (ja) 頻脈の治療
ES2646603T3 (es) Método para tratar la fibrilación auricular
CN109475539B (zh) 帕金森氏病的治疗
JP2012505257A (ja) 多発性硬化症治療のための組成物および方法
US20250188055A1 (en) Acyl Sulfonamides that are BCL Family Antagonists for Use in Clinical Management of Conditions Caused or Mediated by Senescent Cells and for Treating Cancer
JP2014525927A (ja) 治療法に使用される５−ｈｔ４受容体アゴニスト及びｐｄｅ４阻害剤の組合せ
JP2018528251A (ja) 心房細動の予防及び治療のためのドフェチリドとメキシレチンの組合せ
EA027524B1 (ru) Способ ингибирования гиперпроницаемости сосудов при отеке маклы
US20250082688A1 (en) Compositions and methods for williams syndrome (ws) therapy
US20090048173A1 (en) Use Of Dipyridamole For Treatment Of Resistance To Platelet Inhibitors
US20250025444A1 (en) Treatment of neurodegenerative diseases via administration of buntanetap and a phosphodiesterase inhibitor
EA007952B1 (ru) Применение ирбесартана для изготовления лекарств, которые пригодны для предупреждения или лечения лёгочной артериальной гипертензии
US10172854B2 (en) Compositions and methods for treating mitochondrial diseases
Pereira et al. Everolimus for Cardiac Rhabdomyomas in Neonate with Tuberous Sclerosis Complex and Significant Arrhythmias
US20200155495A1 (en) Pharmaceutical compositions and methods utilizing neostigmine and a nk-1 antagonist for treating myasthenia gravis
EP3856185A1 (en) Balipodect for treating or preventing autism spectrum disorders
US11752141B2 (en) Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis
WO2023200738A1 (en) Combination treatment of dilated cardiomyopathy comprising a tyrosine kinase inhibitor and a statin
WO2025221289A1 (en) Treatment of diseases via administration of buntanetap and a phosphodiesterase inhibitor
KR20240045138A (ko) 이나보글리플로진을 포함하는 심혈관 노화 질환 예방 또는 치료용 약학 조성물
HK40086344A (zh) Tau蛋白病的剂量治疗
WO2015105064A1 (ja) 網膜疾患の予防又は治療のための医薬組成物
JP2019514966A (ja) 哺乳動物におけるウイルス感染を処置するための組成物および方法
TW200815381A (en) Methods for treating or reducing muscle fatigue
HK1158984A (en) Use of dronedarone for the preparation of a medicament for the prevention of stroke or transient ischemic attack

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230428

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230704